BLTE vs BOLD

Belite Bio, Inc vs Boundless Bio, Inc. — Valuation Comparison 2026

BLTE

Biotechnology
Belite Bio, Inc
Quality
4.7
out of 10
Value Trap
24
SAFE
Price
$148.00
Last close
Models
10/13
Active
VS

BOLD

Biotechnology
Boundless Bio, Inc.
Quality
4.0
out of 10
Value Trap
18
SAFE
Price
$1.46
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType BLTE Fair ValueBLTE Upside BOLD Fair ValueBOLD Upside
Bayesian DCF Intrinsic $49.41 -66.6% $0.76 -48.1%
Earnings Power Value Intrinsic $77.24 -52.1%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $7.86 -94.7% $2.77 +89.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BLTE vs BOLD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BLTE vs BOLD — Which Stock Is More Undervalued?

BLTE scores higher with a 4.7/10 quality rating vs BOLD's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Belite Bio, Inc (BLTE) and Boundless Bio, Inc. (BOLD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BLTE currently trades at $148.00 with a QOC of 4.7/10, while BOLD trades at $1.46 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).